News By Tag
* Pharmaceutical Sales
* Cnpr Certification
* Sales Representatives
* More Tags...
News By Location
NAPSR news: FDA Approves Anacor Pharma's KERYDIN (Tavaborole) to treat Onychomycosis of the Toenails
Anacor is a biopharmaceutical company whose focus is towards the discovery, development and commercialization of small molecule therapeutics derived from its novel boron chemistry platform.
"We are pleased to announce the FDA approval of KERYDIN, which provides an important new topical treatment option for the millions of people in the United States who are infected with onychomycosis of the toenails," said Paul Berns, Chief Executive Officer of Anacor Pharmaceuticals. "We expect to launch KERYDIN in the U.S., either alone or with a partner, as early as the end of this quarter."
"Onychomycosis is one of the most common diseases diagnosed and treated by podiatrists. Historically, a large number of patients with onychomycosis would choose not to treat their infection," said Warren Joseph, D.P.M., lower extremity Infectious Diseases consultant at Roxborough Memorial Hospital in Philadelphia, Pennsylvania. "With the approval of KERYDIN, physicians can now offer patients a safe, effective and easy-to-use topical treatment for their onychomycosis of the toenail, which I think will be well-received by patients."
"I am very excited about the release of this therapy for an infection that is very difficult to treat," said Boni Elewski, M.D., Vice Chair of Clinical Affairs and Professor of Dermatology at the University of Alabama at Birmingham. "KERYDIN will offer patients a new, safe and effective treatment option for onychomycosis."
"KERYDIN was designed to be convenient for patients to use and has demonstrated efficacy in the treatment of the fungal infection, thus allowing growth of new uninfected nail," stated Vince Ippolito, Chief Commercial Officer of Anacor Pharmaceuticals. "In market research conducted by Anacor, KERYDIN's product profile was received with great enthusiasm by the participating physicians and we believe this response demonstrates the need for a safe topical treatment for onychomycosis of the toenails."
NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders paving the way with new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(